MX2020003575A - Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor. - Google Patents

Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.

Info

Publication number
MX2020003575A
MX2020003575A MX2020003575A MX2020003575A MX2020003575A MX 2020003575 A MX2020003575 A MX 2020003575A MX 2020003575 A MX2020003575 A MX 2020003575A MX 2020003575 A MX2020003575 A MX 2020003575A MX 2020003575 A MX2020003575 A MX 2020003575A
Authority
MX
Mexico
Prior art keywords
pain
alcoxyamino
derivatives
new
related conditions
Prior art date
Application number
MX2020003575A
Other languages
English (en)
Inventor
Rosales Carmen Almansa
Cordobés Félix Cuevas
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MX2020003575A publication Critical patent/MX2020003575A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I) que muestran una gran afinidad y actividad hacia la subunidad a2d de canales de calcio activados por oltaje (VGCC), o actividad doble hacia subunidad a2d de canales de calcio activados por voltaje (VGCC) y el transportador de noradrenalina (NET). La invención también se refiere al procedimiento para la preparación de dichos compuestos así como a composiciones que los comprenden, y a su uso como medicamentos. (ver fórmula).
MX2020003575A 2017-10-27 2018-10-26 Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor. MX2020003575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382721 2017-10-27
PCT/EP2018/079367 WO2019081691A1 (en) 2017-10-27 2018-10-26 NOVEL ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN

Publications (1)

Publication Number Publication Date
MX2020003575A true MX2020003575A (es) 2020-07-22

Family

ID=60262875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003575A MX2020003575A (es) 2017-10-27 2018-10-26 Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.

Country Status (20)

Country Link
US (1) US11401270B2 (es)
EP (1) EP3700890B1 (es)
JP (1) JP2021500416A (es)
KR (1) KR20200097694A (es)
CN (1) CN111566091A (es)
AR (1) AR113799A1 (es)
AU (1) AU2018356556A1 (es)
BR (1) BR112020008371A2 (es)
CA (1) CA3084425A1 (es)
ES (1) ES2905582T3 (es)
IL (1) IL274254A (es)
MA (1) MA50455A (es)
MX (1) MX2020003575A (es)
PH (1) PH12020550594A1 (es)
PT (1) PT3700890T (es)
RU (1) RU2020114523A (es)
SG (1) SG11202003599UA (es)
TW (1) TW201925179A (es)
WO (1) WO2019081691A1 (es)
ZA (1) ZA202002526B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966336B (zh) * 2019-06-06 2023-11-07 和记黄埔医药（上海）有限公司 三环类化合物及其用途
JP2024508372A (ja) * 2021-01-29 2024-02-27 スリールセータ エーハゥーエッフ 注意欠陥／多動性障害の治療又は予防に使用するための化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
AU2003268550A1 (en) * 2002-09-06 2004-03-29 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
JP5026963B2 (ja) * 2004-06-22 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド カルシウムチャネル調整用の複素環誘導体
EP1820799A1 (en) * 2004-11-10 2007-08-22 Wakamoto Pharmaceutical Co., Ltd. 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition
MX2009006234A (es) * 2006-12-11 2009-06-22 Wyeth Corp Moduladores del canal de ion.
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
SI3452475T1 (sl) * 2016-05-06 2020-07-31 Esteve Pharmaceuticals, S.A. Tetrahidropirimidodiazepinske in tetrahidropiridodiazepinske spojine za zdravljenje bolečine in bolečinjskih stanj
CN111225901B (zh) * 2017-10-16 2023-07-04 埃斯特韦制药股份公司 用于治疗疼痛和与疼痛相关的病症的丙胺衍生物

Also Published As

Publication number Publication date
WO2019081691A1 (en) 2019-05-02
AR113799A1 (es) 2020-06-10
SG11202003599UA (en) 2020-05-28
JP2021500416A (ja) 2021-01-07
PT3700890T (pt) 2022-02-02
BR112020008371A2 (pt) 2020-11-03
MA50455A (fr) 2021-06-02
TW201925179A (zh) 2019-07-01
CN111566091A (zh) 2020-08-21
US11401270B2 (en) 2022-08-02
AU2018356556A1 (en) 2020-05-07
RU2020114523A (ru) 2021-12-01
CA3084425A1 (en) 2019-05-02
PH12020550594A1 (en) 2021-02-15
ZA202002526B (en) 2021-06-30
KR20200097694A (ko) 2020-08-19
ES2905582T3 (es) 2022-04-11
IL274254A (en) 2020-06-30
US20200299297A1 (en) 2020-09-24
EP3700890A1 (en) 2020-09-02
EP3700890B1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
NZ731467A (en) Anti-tim3 antibodies and methods of use
GB2541571A (en) Pharmaceutical compositions
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020003770A (es) Terapias de combinacion para tratar cancer.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
CR20190537A (es) Inhibidores pirazólicos de magl
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2020004424A (es) Formulacion aerosolizable.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
IL271728A (en) Materials, uses and treatment methods
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2021006326A (es) Inhibidores de pcna.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.